首页> 美国卫生研究院文献>other >Immunogenicity and transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation
【2h】

Immunogenicity and transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation

机译:肌内电穿孔给药的DNA疫苗编码的Pfs48 / 45和Pfs25的免疫原性和降低传播的效力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pfs48/45 and Pfs25 are leading candidates for the development of Plasmodium falciparum transmission blocking vaccines (TBV). Expression of Pfs48/45 in the erythrocytic sexual stages and presentation to the immune system during infection in the human host also makes it ideal for natural boosting. However, it has been challenging to produce a fully folded, functionally active Pfs48/45, using various protein expression platforms. In this study, we demonstrate that full-length Pfs48/45 encoded by DNA plasmids is able to induce significant transmission reducing immune responses. DNA plasmids encoding Pfs48/45 based on native (WT), codon optimized (SYN), or codon optimized and mutated (MUT1 and MUT2), to prevent any asparagine (N)-linked glycosylation were compared with or without intramuscular electroporation (EP). EP significantly enhanced antibody titers and transmission blocking activity elicited by immunization with SYN Pfs48/45 DNA vaccine. Mosquito membrane feeding assays also revealed improved functional immunogenicity of SYN Pfs48/45 (N-glycosylation sites intact) as compared to MUT1 or MUT2 Pfs48/45 DNA plasmids (all N-glycosylation sites mutated). Boosting with recombinant Pfs48/45 protein after immunization with each of the different DNA vaccines resulted in significant boosting of antibody response and improved transmission reducing capabilities of all four DNA vaccines. Finally, immunization with a combination of DNA plasmids (SYN Pfs48/45 and SYN Pfs25) also provides support for the possibility of combining antigens targeting different life cycle stages in the parasite during transmission through mosquitoes.
机译:Pfs48 / 45和Pfs25是开发恶性疟原虫传播阻断疫苗(TBV)的主要候选药物。 Pfs48 / 45在红细胞性阶段的表达以及在人类宿主感染过程中向免疫系统的呈递也使其成为自然免疫的理想选择。然而,使用各种蛋白质表达平台生产完全折叠的,具有功能活性的Pfs48 / 45一直是一项挑战。在这项研究中,我们证明了由DNA质粒编码的全长Pfs48 / 45能够诱导明显的传播,从而降低免疫反应。比较了基于天然(WT),密码子优化(SYN)或密码子优化和突变(MUT1和MUT2)来编码Pfs48 / 45的DNA质粒,以防止有或没有肌内电穿孔(EP)的天冬酰胺(N)连锁糖基化。 EP显着增强了用SYN Pfs48 / 45 DNA疫苗免疫引起的抗体滴度和传递阻断活性。与MUT1或MUT2 Pfs48 / 45 DNA质粒(所有N-糖基化位点均发生突变)相比,蚊膜饲喂测定法还揭示了SYN Pfs48 / 45(完整的N-糖基化位点)的功能免疫原性。在用每种不同的DNA疫苗免疫后,用重组Pfs48 / 45蛋白加强免疫可显着增强抗体应答并改善所有四种DNA疫苗的递减传播能力。最后,用DNA质粒(SYN Pfs48 / 45和SYN Pfs25)的组合进行免疫也为在蚊子传播期间在寄生虫中结合靶向不同生命周期阶段的抗原的可能性提供了支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号